Droperidol's effect on QT interval.
The Food and Drug Administration (FDA) issued a letter to health care providers on December 4, 2001, concerning the medication, droperidol. The purpose of the warning was to alert health care providers to the possible role of droperidol in the development of torsades de pointes (TdP) in susceptible patients. The purpose of this article is to explore the role of droperidol in the development of TdP in susceptible patients and current recommendations for the use of droperidol as an antiemetic.
Martinez
Jason B
JB
Kearney Anesthesia Associates, PC, Kearney, NE 68847, USA. jasonbmartinez@yahoo.com
Moos
Daniel D
DD
Dahlen
Larry L
LL
D000759:Adjuvants, Anesthesia / Q000009:adverse effects*; D016907:Adverse Drug Reaction Reporting Systems; D000932:Antiemetics / Q000009:adverse effects*; D000075202:Contraindications; D004329:Droperidol / Q000009:adverse effects*; D004348:Drug Labeling; D016903:Drug Monitoring; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000628:therapy; D024802:Nurse's Role; D016528:Postanesthesia Nursing / Q000458:organization & administration; D012307:Risk Factors; D016171:Torsades de Pointes / Q000139:chemically induced* / Q000628:therapy; D014481:United States; D014486:United States Food and Drug Administration
D000759:Adjuvants, Anesthesia; D000932:Antiemetics; D004329:Droperidol